Q-omics provides the consensus-scored DCAF8L1 profile across patient tissues and cancer cell-line models. DCAF8L1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DCAF8L1 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, DCAF8L1 RNA expression shows 7,460 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LIHC, and TGCT as cancer lineages where DCAF8L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF8L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF8L1 survival associations across molecular data types. DCAF8L1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF8L1 RNA expression–survival associations across cancer types. High DCAF8L1 expression shows unfavorable associations in UCEC, THYM, KICH, DLBC and THCA, but favorable associations in CESC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DCAF8L1 RNA expression.
This table summarizes DCAF8L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for DCAF8L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF8L1 shows higher tumor expression in LIHC. The LIHC box plot shows higher DCAF8L1 RNA expression in tumor versus normal tissue (log2 FC = +0.310, t-test p = .003).
This table shows molecular features associated with DCAF8L1 in patient tissues and cancer cell lines. In patient samples, DCAF8L1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF8L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
